LEVETIRACETAM IN SODIUM CHLORIDE
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability.
| Metabolism | Levetiracetam is primarily eliminated renally; approximately 24% undergoes metabolism by hydrolysis of the acetamide group, not dependent on CYP450 enzymes. |
| Excretion | 66% renal (unchanged), 27% as inactive metabolite (UCB L057) via renal; <1% fecal |
| Half-life | 6-8 hours in adults; prolonged in elderly (10-11 h) and renal impairment (up to 25 h in ESRD) |
| Protein binding | <10% (negligible); not bound to albumin or alpha-1-acid glycoprotein |
| Volume of Distribution | 0.5-0.7 L/kg; approximates total body water, indicating extensive distribution into tissues and CNS |
| Bioavailability | IV: 100%; Oral: 100% (rapid and complete absorption) |
| Onset of Action | IV: within 5-15 minutes after infusion; Oral: 1-2 hours |
| Duration of Action | IV: 4-6 hours (seizure protection); Oral: 6-8 hours (steady-state trough concentrations maintained for twice-daily dosing) |
| Molecular Weight | 170.21 |
500-1500 mg IV every 12 hours; initial dose 1000 mg/day, titrate by 1000 mg/day every 2 weeks up to 3000 mg/day.
| Dosage form | INJECTABLE |
| Renal impairment | CrCl >80 mL/min: 500-1500 mg every 12h; CrCl 50-80: 500-1000 mg every 12h; CrCl 30-50: 250-750 mg every 12h; CrCl <30: 250-500 mg every 12h; ESRD: 500-1000 mg every 24h with 250-500 mg supplement post-dialysis. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Severe impairment (Child-Pugh C): reduce maintenance dose by 50%. |
| Pediatric use | 1 month to <6 months: 7 mg/kg/dose IV every 12h; 6 months to <4 years: 10 mg/kg/dose IV every 12h; 4 to <16 years: 10 mg/kg/dose IV every 12h up to 30 mg/kg/day. Maximum 3000 mg/day. |
| Geriatric use | Initiate at 500 mg twice daily, titrate slowly due to age-related renal function decline; adjust dose per creatinine clearance. |
| 1st trimester | Increased risk of major congenital malformations, particularly neural tube defects, cleft palate, and cardiac anomalies; use only if benefit outweighs risk. |
| 2nd trimester | Continued risk of teratogenicity; fetal growth restriction and neurodevelopmental effects may occur; monitor fetal growth and adjust dose as needed. |
| 3rd trimester | Risk of neonatal hemorrhage, sedation, and withdrawal symptoms; neonatal vitamin K recommended; avoid abrupt discontinuation. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Levetiracetam crosses the placenta with cord blood levels approximately 50-100% of maternal plasma levels; distribution to fetal tissues is extensive. |
| Breastfeeding | Levetiracetam is excreted into breast milk but levels are lower than therapeutic doses; monitor infant for drowsiness, poor feeding, and weight gain; generally considered compatible with breastfeeding. |
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | Levetiracetam is associated with an increased risk of major congenital malformations, particularly neural tube defects, when used during the first trimester. Exposure in the second and third trimesters may lead to fetal growth restriction and neurodevelopmental effects. The risk appears dose-dependent. |
| Fetal Monitoring | Monitor maternal serum levels of levetiracetam due to decreased drug concentrations during pregnancy. Perform fetal ultrasound for neural tube defects and growth. Consider neurodevelopmental follow-up for the child after birth. |
| Fertility Effects | Levetiracetam does not appear to have significant adverse effects on human fertility. Animal studies show no impairment of fertility at clinically relevant doses. |
■ FDA Black Box Warning
No FDA black box warnings.
| Common Effects | fluid replacement |
| Serious Effects |
Hypersensitivity to levetiracetam or any component of the formulation
| Precautions | Behavioral and psychiatric symptoms: aggression, agitation, anger, anxiety, depression, mood swings, psychosis, suicidal ideation, Somnolence and fatigue, Serious dermatological reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), Hematologic abnormalities (e.g., decreased white blood cell counts), Hypersensitivity reactions including angioedema, Renal impairment requires dose adjustment |
| Food/Dietary | No significant food interactions. Levetiracetam can be taken with or without food. Avoid excessive alcohol consumption as it may increase CNS depression. |
| Clinical Pearls | Monitor for behavioral and psychiatric symptoms, especially in pediatric patients. Infusion rate should not exceed 5 mg/kg/min. Risk of suicidal thoughts and behavior. Caution in renal impairment; adjust dose based on creatinine clearance. Levetiracetam is not significantly protein-bound and has minimal drug interactions. May cause somnolence, dizziness, and coordination difficulties. |
| Patient Advice | Report any new or worsening depression, agitation, hostility, or suicidal thoughts immediately. · Do not drive or operate heavy machinery until you know how levetiracetam affects you; it may cause dizziness or sleepiness. · If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; do not double dose. · Do not stop taking levetiracetam abruptly; this can increase seizure frequency. · Inform all healthcare providers that you take levetiracetam, especially before surgery or emergency treatment. |
Loading safety data…